APO Research
Talk to an analyst

APO RESEARCH · REPORT

Long-acting rhG-CSF

Compare research editions
View pricing & licenses

Selected research

Industry Growth & Trends

Global Long-acting rhG-CSF Industry Growth and Trends Forecast to 2032

23 December 2025100 pages

Choose your research edition.

Industry ResearchLong-acting rhG-CSF Industry Research Report 2026126 pages · $2,950 USDIndustry Growth & TrendsGlobal Long-acting rhG-CSF Industry Growth and Trends Forecast to 2032100 pages · $3,450 USDMarket StructureGlobal Long-acting rhG-CSF Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032198 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Long-acting rhG-CSF Market Outlook and Growth Opportunities 2026199 pages · $4,250 USDMarket Analysis & ForecastGlobal Long-acting rhG-CSF Market Analysis and Forecast 2026-2032190 pages · $4,950 USD

Market perspective

The global Long-acting rhG-CSF market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The North America market for Long-acting rhG-CSF is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.

The Europe market for Long-acting rhG-CSF is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Long-acting rhG-CSF is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Long-acting rhG-CSF include Yifan Pharmaceutical, CSPC, Sandoz (Novartis), Qilu Pharmaceutical, Mylan, Pfizer, Jiangsu Hengrui Medicine, Fresenius Kabi and Amgen Inc., among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report provides a structured, data-driven view of the global Long-acting rhG-CSF market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The Long-acting rhG-CSF market size, estimates, and forecasts are presented in terms of sales volume (units) and revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Long-acting rhG-CSF market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Long-acting rhG-CSF.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading manufacturers in the global Long-acting rhG-CSF market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue, price, and sales volume data by manufacturer for 2020-2025, enabling benchmarking of scale, pricing, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

Long-acting rhG-CSF Market by Company

Yifan Pharmaceutical

CSPC

Sandoz (Novartis)

Qilu Pharmaceutical

Mylan

Pfizer

Jiangsu Hengrui Medicine

Fresenius Kabi

Amgen Inc.

Spectrum Pharmaceuticals

Coherus BioSciences, Inc.

Biocon Biologics Inc.

Long-acting rhG-CSF Segment by Type

Long-acting rhG-CSF

Long-acting PEG-rhG-CSF

Long-acting rhG-CSF Segment by Application

Blood Disorders

Neoplastic Diseases

Others

Long-acting rhG-CSF Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Long-acting rhG-CSF market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Long-acting rhG-CSF and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Long-acting rhG-CSF.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Long-acting rhG-CSF manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Sales, revenue of Long-acting rhG-CSF in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.

Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.

Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.

Chapter 13: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Major Company of Long-acting rhG-CSF Table 2. Major Company of Long-acting PEG-rhG-CSF Table 3. Global Long-acting rhG-CSF Sales by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 4. Global Long-acting rhG-CSF Sales by Type (2021-2026) & (units) Table 5. Global Long-acting rhG-CSF Sales Market Share in Volume by Type (2021-2026) Table 6. Global Long-acting rhG-CSF Sales by Type (2021-2026) & (US$ Million) Table 7. Global Long-acting rhG-CSF Sales Market Share in Value by Type (2021-2026) Table 8. Global Long-acting rhG-CSF Price by Type (2021-2026) & (USD/unit) Table 9. Global Long-acting rhG-CSF Sales by Type (2027-2032) & (units) Table 10. Global Long-acting rhG-CSF Sales Market Share in Volume by Type (2027-2032) Table 11. Global Long-acting rhG-CSF Sales by Type (2027-2032) & (US$ Million) Table 12. Global Long-acting rhG-CSF Sales Market Share in Value by Type (2027-2032) Table 13. Global Long-acting rhG-CSF Price by Type (2027-2032) & (USD/unit) Table 14. North America Long-acting rhG-CSF Sales by Type (2021-2026) & (units) Table 15. North America Long-acting rhG-CSF Sales by Type (2021-2026) & (US$ Million) Table 16. Europe Long-acting rhG-CSF Sales by Type (2021-2026) & (units) Table 17. Europe Long-acting rhG-CSF Sales by Type (2021-2026) & (US$ Million) Table 18. Asia-Pacific Long-acting rhG-CSF Sales by Type (2021-2026) & (units) Table 19. Asia-Pacific Long-acting rhG-CSF Sales by Type (2021-2026) & (US$ Million) Table 20. Latin America Long-acting rhG-CSF Sales by Type (2021-2026) & (units) Table 21. Latin America Long-acting rhG-CSF Sales by Type (2021-2026) & (US$ Million) Table 22. Middle East and Africa Long-acting rhG-CSF Sales by Type (2021-2026) & (units) Table 23. Middle East and Africa Long-acting rhG-CSF Sales by Type (2021-2026) & (US$ Million) Table 24. Long-acting rhG-CSF Industry Trends Table 25. Long-acting rhG-CSF Industry Drivers Table 26. Long-acting rhG-CSF Industry Opportunities and Challenges Table 27. Long-acting rhG-CSF Industry Restraints Table 28. Global Long-acting rhG-CSF Sales Revenue by Company (US$ Million) & (2021-2026) Table 29. Global Long-acting rhG-CSF Revenue Market Share by Company (2021-2026) Table 30. Global Long-acting rhG-CSF Sales by Company (2021-2026) & (units) Table 31. Global Long-acting rhG-CSF Sales Share by Company (2021-2026) Table 32. Global Long-acting rhG-CSF Market Price by Company (2021-2026) & (USD/unit) Table 33. Global Long-acting rhG-CSF Industry Company Ranking, 2024 VS 2025 VS 2026 Table 34. Global Long-acting rhG-CSF Major Company Production Sites and Headquarters Table 35. Global Long-acting rhG-CSF Company, Product Type & Application Table 36. Global Long-acting rhG-CSF Company Establishment Date Table 37. Global Company Market Concentration Ratio (CR5 and HHI) Table 38. Global Long-acting rhG-CSF by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 39. Global Long-acting rhG-CSF Market Size Comparison by Region (US$ Million): 2021 VS 2025 VS 2032 Table 40. Global Long-acting rhG-CSF Sales by Region (2021-2026) & (units) Table 41. Global Long-acting rhG-CSF Sales Market Share in Volume by Region (2021-2026) Table 42. Global Long-acting rhG-CSF Sales by Region (2021-2026) & (US$ Million) Table 43. Global Long-acting rhG-CSF Sales Market Share in Value by Region (2021-2026) Table 44. Global Long-acting rhG-CSF Sales (units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 45. Global Long-acting rhG-CSF Sales by Region (2027-2032) & (units) Table 46. Global Long-acting rhG-CSF Sales Market Share in Volume by Region (2027-2032) Table 47. Global Long-acting rhG-CSF Sales by Region (2027-2032) & (US$ Million) Table 48. Global Long-acting rhG-CSF Sales Market Share in Value by Region (2027-2032) Table 49. Global Long-acting rhG-CSF Sales (units), Value (US$ Million), Price (USD/unit) and Gross Margin (2027-2032) Table 50. Global Long-acting rhG-CSF Sales by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 51. Global Long-acting rhG-CSF Sales by Application (2021-2026) & (units) Table 52. Global Long-acting rhG-CSF Sales Market Share in Volume by Application (2021-2026) Table 53. Global Long-acting rhG-CSF Sales by Application (2021-2026) & (US$ Million) Table 54. Global Long-acting rhG-CSF Sales Market Share in Value by Application (2021-2026) Table 55. Global Long-acting rhG-CSF Price by Application (2021-2026) & (USD/unit) Table 56. Global Long-acting rhG-CSF Sales by Application (2027-2032) & (units) Table 57. Global Long-acting rhG-CSF Sales Market Share in Volume by Application (2027-2032) Table 58. Global Long-acting rhG-CSF Sales by Application (2027-2032) & (US$ Million) Table 59. Global Long-acting rhG-CSF Sales Market Share in Value by Application (2027-2032) Table 60. Global Long-acting rhG-CSF Price by Application (2027-2032) & (USD/unit) Table 61. North America Long-acting rhG-CSF Sales by Application (2021-2026) & (units) Table 62. North America Long-acting rhG-CSF Sales by Application (2021-2026) & (US$ Million) Table 63. Europe Long-acting rhG-CSF Sales by Application (2021-2026) & (units) Table 64. Europe Long-acting rhG-CSF Sales by Application (2021-2026) & (US$ Million) Table 65. Asia-Pacific Long-acting rhG-CSF Sales by Application (2021-2026) & (units) Table 66. Asia-Pacific Long-acting rhG-CSF Sales by Application (2021-2026) & (US$ Million) Table 67. Latin America Long-acting rhG-CSF Sales by Application (2021-2026) & (units) Table 68. Latin America Long-acting rhG-CSF Sales by Application (2021-2026) & (US$ Million) Table 69. Middle East and Africa Long-acting rhG-CSF Sales by Application (2021-2026) & (units) Table 70. Middle East and Africa Long-acting rhG-CSF Sales by Application (2021-2026) & (US$ Million) Table 71. Yifan Pharmaceutical Company Information Table 72. Yifan Pharmaceutical Business Overview Table 73. Yifan Pharmaceutical Long-acting rhG-CSF Sales (units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 74. Yifan Pharmaceutical Long-acting rhG-CSF Product Portfolio Table 75. Yifan Pharmaceutical Recent Development Table 76. CSPC Company Information Table 77. CSPC Business Overview Table 78. CSPC Long-acting rhG-CSF Sales (units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 79. CSPC Long-acting rhG-CSF Product Portfolio Table 80. CSPC Recent Development Table 81. Sandoz (Novartis) Company Information Table 82. Sandoz (Novartis) Business Overview Table 83. Sandoz (Novartis) Long-acting rhG-CSF Sales (units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 84. Sandoz (Novartis) Long-acting rhG-CSF Product Portfolio Table 85. Sandoz (Novartis) Recent Development Table 86. Qilu Pharmaceutical Company Information Table 87. Qilu Pharmaceutical Business Overview Table 88. Qilu Pharmaceutical Long-acting rhG-CSF Sales (units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 89. Qilu Pharmaceutical Long-acting rhG-CSF Product Portfolio Table 90. Qilu Pharmaceutical Recent Development Table 91. Mylan Company Information Table 92. Mylan Business Overview Table 93. Mylan Long-acting rhG-CSF Sales (units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 94. Mylan Long-acting rhG-CSF Product Portfolio Table 95. Mylan Recent Development Table 96. Pfizer Company Information Table 97. Pfizer Business Overview Table 98. Pfizer Long-acting rhG-CSF Sales (units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 99. Pfizer Long-acting rhG-CSF Product Portfolio Table 100. Pfizer Recent Development Table 101. Jiangsu Hengrui Medicine Company Information Table 102. Jiangsu Hengrui Medicine Business Overview Table 103. Jiangsu Hengrui Medicine Long-acting rhG-CSF Sales (units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 104. Jiangsu Hengrui Medicine Long-acting rhG-CSF Product Portfolio Table 105. Jiangsu Hengrui Medicine Recent Development Table 106. Fresenius Kabi Company Information Table 107. Fresenius Kabi Business Overview Table 108. Fresenius Kabi Long-acting rhG-CSF Sales (units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 109. Fresenius Kabi Long-acting rhG-CSF Product Portfolio Table 110. Fresenius Kabi Recent Development Table 111. Amgen Inc. Company Information Table 112. Amgen Inc. Business Overview Table 113. Amgen Inc. Long-acting rhG-CSF Sales (units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 114. Amgen Inc. Long-acting rhG-CSF Product Portfolio Table 115. Amgen Inc. Recent Development Table 116. Spectrum Pharmaceuticals Company Information Table 117. Spectrum Pharmaceuticals Business Overview Table 118. Spectrum Pharmaceuticals Long-acting rhG-CSF Sales (units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 119. Spectrum Pharmaceuticals Long-acting rhG-CSF Product Portfolio Table 120. Spectrum Pharmaceuticals Recent Development Table 121. Coherus BioSciences, Inc. Company Information Table 122. Coherus BioSciences, Inc. Business Overview Table 123. Coherus BioSciences, Inc. Long-acting rhG-CSF Sales (units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 124. Coherus BioSciences, Inc. Long-acting rhG-CSF Product Portfolio Table 125. Coherus BioSciences, Inc. Recent Development Table 126. Biocon Biologics Inc. Company Information Table 127. Biocon Biologics Inc. Business Overview Table 128. Biocon Biologics Inc. Long-acting rhG-CSF Sales (units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 129. Biocon Biologics Inc. Long-acting rhG-CSF Product Portfolio Table 130. Biocon Biologics Inc. Recent Development Table 131. North America Long-acting rhG-CSF Market Size Growth Rate (CAGR) by Country (units): 2021 VS 2025 VS 2032 Table 132. North America Long-acting rhG-CSF Sales by Country (2021-2026) & (units) Table 133. North America Long-acting rhG-CSF Sales Market Share by Country (2021-2026) Table 134. North America Long-acting rhG-CSF Sales Forecast by Country (2027-2032) & (units) Table 135. North America Long-acting rhG-CSF Sales Market Share Forecast by Country (2027-2032) Table 136. North America Long-acting rhG-CSF Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 137. North America Long-acting rhG-CSF Market Size by Country (2021-2026) & (US$ Million) Table 138. North America Long-acting rhG-CSF Market Share by Country (2021-2026) Table 139. North America Long-acting rhG-CSF Market Size Forecast by Country (2027-2032) & (US$ Million) Table 140. North America Long-acting rhG-CSF Market Share Forecast by Country (2027-2032) Table 141. Europe Long-acting rhG-CSF Market Size Growth Rate (CAGR) by Country (units): 2021 VS 2025 VS 2032 Table 142. Europe Long-acting rhG-CSF Sales by Country (2021-2026) & (units) Table 143. Europe Long-acting rhG-CSF Sales Market Share by Country (2021-2026) Table 144. Europe Long-acting rhG-CSF Sales Forecast by Country (2027-2032) & (units) Table 145. Europe Long-acting rhG-CSF Sales Market Share Forecast by Country (2027-2032) Table 146. Europe Long-acting rhG-CSF Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 147. Europe Long-acting rhG-CSF Market Size by Country (2021-2026) & (US$ Million) Table 148. Europe Long-acting rhG-CSF Market Share by Country (2021-2026) Table 149. Europe Long-acting rhG-CSF Market Size Forecast by Country (2027-2032) & (US$ Million) Table 150. Europe Long-acting rhG-CSF Market Share Forecast by Country (2027-2032) Table 151. Asia-Pacific Long-acting rhG-CSF Market Size Growth Rate (CAGR) by Country (units): 2021 VS 2025 VS 2032 Table 152. Asia-Pacific Long-acting rhG-CSF Sales by Country (2021-2026) & (units) Table 153. Asia-Pacific Long-acting rhG-CSF Sales Market Share by Country (2021-2026) Table 154. Asia-Pacific Long-acting rhG-CSF Sales Forecast by Country (2027-2032) & (units) Table 155. Asia-Pacific Long-acting rhG-CSF Sales Market Share Forecast by Country (2027-2032) Table 156. Asia-Pacific Long-acting rhG-CSF Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 157. Asia-Pacific Long-acting rhG-CSF Market Size by Country (2021-2026) & (US$ Million) Table 158. Asia-Pacific Long-acting rhG-CSF Market Share by Country (2021-2026) Table 159. Asia-Pacific Long-acting rhG-CSF Market Size Forecast by Country (2027-2032) & (US$ Million) Table 160. Asia-Pacific Long-acting rhG-CSF Market Share Forecast by Country (2027-2032) Table 161. Latin America Long-acting rhG-CSF Market Size Growth Rate (CAGR) by Country (units): 2021 VS 2025 VS 2032 Table 162. Latin America Long-acting rhG-CSF Sales by Country (2021-2026) & (units) Table 163. Latin America Long-acting rhG-CSF Sales Market Share by Country (2021-2026) Table 164. Latin America Long-acting rhG-CSF Sales Forecast by Country (2027-2032) & (units) Table 165. Latin America Long-acting rhG-CSF Sales Market Share Forecast by Country (2027-2032) Table 166. Latin America Long-acting rhG-CSF Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 167. Latin America Long-acting rhG-CSF Market Size by Country (2021-2026) & (US$ Million) Table 168. Latin America Long-acting rhG-CSF Market Share by Country (2021-2026) Table 169. Latin America Long-acting rhG-CSF Market Size Forecast by Country (2027-2032) & (US$ Million) Table 170. Latin America Long-acting rhG-CSF Market Share Forecast by Country (2027-2032) Table 171. Middle East and Africa Long-acting rhG-CSF Market Size Growth Rate (CAGR) by Country (units): 2021 VS 2025 VS 2032 Table 172. Middle East and Africa Long-acting rhG-CSF Sales by Country (2021-2026) & (units) Table 173. Middle East and Africa Long-acting rhG-CSF Sales Market Share by Country (2021-2026) Table 174. Middle East and Africa Long-acting rhG-CSF Sales Forecast by Country (2027-2032) & (units) Table 175. Middle East and Africa Long-acting rhG-CSF Sales Market Share Forecast by Country (2027-2032) Table 176. Middle East and Africa Long-acting rhG-CSF Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 177. Middle East and Africa Long-acting rhG-CSF Market Size by Country (2021-2026) & (US$ Million) Table 178. Middle East and Africa Long-acting rhG-CSF Market Share by Country (2021-2026) Table 179. Middle East and Africa Long-acting rhG-CSF Market Size Forecast by Country (2027-2032) & (US$ Million) Table 180. Middle East and Africa Long-acting rhG-CSF Market Share Forecast by Country (2027-2032) Table 181. Key Raw Materials Table 182. Raw Materials Key Suppliers Table 183. Long-acting rhG-CSF Distributors List Table 184. Long-acting rhG-CSF Customers List Table 185. Research Programs/Design for This Report Table 186. Authors List of This Report Table 187. Secondary Sources Table 188. Primary Sources List of Figures Figure 1. Long-acting rhG-CSF Image Figure 2. Global Long-acting rhG-CSF Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Long-acting rhG-CSF Market Size (2021-2032) & (US$ Million) Figure 4. Global Long-acting rhG-CSF Sales (2021-2032) & (units) Figure 5. Long-acting rhG-CSF Image Figure 6. Global Long-acting rhG-CSF Sales YoY Growth (2021-2032) & (units) Figure 7. Long-acting PEG-rhG-CSF Image Figure 8. Global Long-acting PEG-rhG-CSF Sales YoY Growth (2021-2032) & (units) Figure 9. Global Long-acting rhG-CSF Market Size Overview by Type (2021-2032) & (US$ Million) Figure 10. Global Long-acting rhG-CSF Market Share by Type 2025 VS 2032 Figure 11. North America Long-acting rhG-CSF Sales Market Share in Volume by Type in 2025 Figure 12. North America Long-acting rhG-CSF Sales Market Share in Value by Type in 2025 Figure 13. Europe Long-acting rhG-CSF Sales Market Share in Volume by Type in 2025 Figure 14. Europe Long-acting rhG-CSF Sales Market Share in Value by Type in 2025 Figure 15. Asia-Pacific Long-acting rhG-CSF Sales Market Share in Volume by Type in 2025 Figure 16. Asia-Pacific Long-acting rhG-CSF Sales Market Share in Value by Type in 2025 Figure 17. Latin America Long-acting rhG-CSF Sales Market Share in Volume by Type in 2025 Figure 18. Latin America Long-acting rhG-CSF Sales Market Share in Value by Type in 2025 Figure 19. Middle East and Africa Long-acting rhG-CSF Sales Market Share in Volume by Type in 2025 Figure 20. Middle East and Africa Long-acting rhG-CSF Sales Market Share in Value by Type in 2025 Figure 21. Global Top 5 and 10 Long-acting rhG-CSF Players Market Share by Revenue in 2025 Figure 22. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 23. Blood Disorders Image Figure 24. Global Blood Disorders Sales YoY Growth (2021-2032) & (units) Figure 25. Neoplastic Diseases Image Figure 26. Global Neoplastic Diseases Sales YoY Growth (2021-2032) & (units) Figure 27. Others Image Figure 28. Global Others Sales YoY Growth (2021-2032) & (units) Figure 29. Global Long-acting rhG-CSF Market Size Overview by Application (2021-2032) & (US$ Million) Figure 30. Global Long-acting rhG-CSF Market Share by Application 2025 VS 2032 Figure 31. North America Long-acting rhG-CSF Sales Market Share in Volume by Application in 2025 Figure 32. North America Long-acting rhG-CSF Sales Market Share in Value by Application in 2025 Figure 33. Europe Long-acting rhG-CSF Sales Market Share in Volume by Application in 2025 Figure 34. Europe Long-acting rhG-CSF Sales Market Share in Value by Application in 2025 Figure 35. Asia-Pacific Long-acting rhG-CSF Sales Market Share in Volume by Application in 2025 Figure 36. Asia-Pacific Long-acting rhG-CSF Sales Market Share in Value by Application in 2025 Figure 37. Latin America Long-acting rhG-CSF Sales Market Share in Volume by Application in 2025 Figure 38. Latin America Long-acting rhG-CSF Sales Market Share in Value by Application in 2025 Figure 39. Middle East and Africa Long-acting rhG-CSF Sales Market Share in Volume by Application in 2025 Figure 40. Middle East and Africa Long-acting rhG-CSF Sales Market Share in Value by Application in 2025 Figure 41. North America Long-acting rhG-CSF Sales by Country: 2021 VS 2025 VS 2032 (units) Figure 42. North America Long-acting rhG-CSF Sales Share by Country: 2021 VS 2025 VS 2032 Figure 43. North America Long-acting rhG-CSF Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 44. North America Long-acting rhG-CSF Market Share by Country: 2021 VS 2025 VS 2032 Figure 45. Europe Long-acting rhG-CSF Sales by Country: 2021 VS 2025 VS 2032 (units) Figure 46. Europe Long-acting rhG-CSF Sales Share by Country: 2021 VS 2025 VS 2032 Figure 47. Europe Long-acting rhG-CSF Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 48. Europe Long-acting rhG-CSF Market Share by Country: 2021 VS 2025 VS 2032 Figure 49. Asia-Pacific Long-acting rhG-CSF Sales by Country: 2021 VS 2025 VS 2032 (units) Figure 50. Asia-Pacific Long-acting rhG-CSF Sales Share by Country: 2021 VS 2025 VS 2032 Figure 51. Asia-Pacific Long-acting rhG-CSF Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 52. Asia-Pacific Long-acting rhG-CSF Market Share by Country: 2021 VS 2025 VS 2032 Figure 53. Latin America Long-acting rhG-CSF Sales by Country: 2021 VS 2025 VS 2032 (units) Figure 54. Latin America Long-acting rhG-CSF Sales Share by Country: 2021 VS 2025 VS 2032 Figure 55. Latin America Long-acting rhG-CSF Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 56. Latin America Long-acting rhG-CSF Market Share by Country: 2021 VS 2025 VS 2032 Figure 57. Middle East and Africa Long-acting rhG-CSF Sales by Country: 2021 VS 2025 VS 2032 (units) Figure 58. Middle East and Africa Long-acting rhG-CSF Sales Share by Country: 2021 VS 2025 VS 2032 Figure 59. Middle East and Africa Long-acting rhG-CSF Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 60. Middle East and Africa Long-acting rhG-CSF Market Share by Country: 2021 VS 2025 VS 2032 Figure 61. Long-acting rhG-CSF Value Chain Figure 62. Key Raw Materials Price Figure 63. Manufacturing Cost Structure Figure 64. Long-acting rhG-CSF Production Mode & Process Figure 65. Direct Comparison with Distribution Share Figure 66. Distributors Profiles Figure 67. Years Considered Figure 68. Research Process Figure 69. Key Executives Interviewed

Scope & coverage.

Types
  • Long-acting rhG-CSF
  • Long-acting PEG-rhG-CSF
Applications
  • Blood Disorders
  • Neoplastic Diseases
  • Others
Companies covered
  • Yifan Pharmaceutical
  • CSPC
  • Sandoz (Novartis)
  • Qilu Pharmaceutical
  • Mylan
  • Pfizer
  • Jiangsu Hengrui Medicine
  • Fresenius Kabi
  • Amgen Inc.
  • Spectrum Pharmaceuticals
  • Coherus BioSciences, Inc.
  • Biocon Biologics Inc.

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Long-acting rhG-CSF Market Size Estimates and Forecasts (2021-2032)
  4. 1.2.2 Global Long-acting rhG-CSF Sales Estimates and Forecasts (2021-2032)
  5. 1.3 Long-acting rhG-CSF Market by Type
  6. 1.3.1 Long-acting rhG-CSF
  7. 1.3.2 Long-acting PEG-rhG-CSF
  8. 1.4 Global Long-acting rhG-CSF Market Size by Type
  9. 1.4.1 Global Long-acting rhG-CSF Market Size Overview by Type (2021-2032)
  10. 1.4.2 Global Long-acting rhG-CSF Historic Market Size Review by Type (2021-2026)
  11. 1.4.3 Global Long-acting rhG-CSF Forecasted Market Size by Type (2027-2032)
  12. 1.5 Key Regions Market Size by Type
  13. 1.5.1 North America Long-acting rhG-CSF Sales Breakdown by Type (2021-2026)
  14. 1.5.2 Europe Long-acting rhG-CSF Sales Breakdown by Type (2021-2026)
  15. 1.5.3 Asia-Pacific Long-acting rhG-CSF Sales Breakdown by Type (2021-2026)
  16. 1.5.4 South America Long-acting rhG-CSF Sales Breakdown by Type (2021-2026)
  17. 1.5.5 Middle East and Africa Long-acting rhG-CSF Sales Breakdown by Type (2021-2026)
2 Global Market Dynamics
  1. 2.1 Long-acting rhG-CSF Industry Trends
  2. 2.2 Long-acting rhG-CSF Industry Drivers
  3. 2.3 Long-acting rhG-CSF Industry Opportunities and Challenges
  4. 2.4 Long-acting rhG-CSF Industry Restraints
3 Market Competitive Landscape by Company
  1. 3.1 Global Top Players by Long-acting rhG-CSF Revenue (2021-2026)
  2. 3.2 Global Top Players by Long-acting rhG-CSF Sales (2021-2026)
  3. 3.3 Global Top Players by Long-acting rhG-CSF Price (2021-2026)
  4. 3.4 Global Long-acting rhG-CSF Industry Company Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Long-acting rhG-CSF Major Company Production Sites & Headquarters
  6. 3.6 Global Long-acting rhG-CSF Company, Product Type & Application
  7. 3.7 Global Long-acting rhG-CSF Company Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Long-acting rhG-CSF Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Long-acting rhG-CSF Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Long-acting rhG-CSF Tier 1, Tier 2, and Tier 3
4 Long-acting rhG-CSF Regional Status and Outlook
  1. 4.1 Global Long-acting rhG-CSF Market Size and CAGR by Region: 2021 VS 2025 VS 2032
  2. 4.2 Global Long-acting rhG-CSF Historic Market Size by Region
  3. 4.2.1 Global Long-acting rhG-CSF Sales in Volume by Region (2021-2026)
  4. 4.2.2 Global Long-acting rhG-CSF Sales in Value by Region (2021-2026)
  5. 4.2.3 Global Long-acting rhG-CSF Sales (Volume & Value), Price and Gross Margin (2021-2026)
  6. 4.3 Global Long-acting rhG-CSF Forecasted Market Size by Region
  7. 4.3.1 Global Long-acting rhG-CSF Sales in Volume by Region (2027-2032)
  8. 4.3.2 Global Long-acting rhG-CSF Sales in Value by Region (2027-2032)
  9. 4.3.3 Global Long-acting rhG-CSF Sales (Volume & Value), Price and Gross Margin (2027-2032)
5 Long-acting rhG-CSF by Application
  1. 5.1 Long-acting rhG-CSF Market by Application
  2. 5.1.1 Blood Disorders
  3. 5.1.2 Neoplastic Diseases
  4. 5.1.3 Others
  5. 5.2 Global Long-acting rhG-CSF Market Size by Application
  6. 5.2.1 Global Long-acting rhG-CSF Market Size Overview by Application (2021-2032)
  7. 5.2.2 Global Long-acting rhG-CSF Historic Market Size Review by Application (2021-2026)
  8. 5.2.3 Global Long-acting rhG-CSF Forecasted Market Size by Application (2027-2032)
  9. 5.3 Key Regions Market Size by Application
  10. 5.3.1 North America Long-acting rhG-CSF Sales Breakdown by Application (2021-2026)
  11. 5.3.2 Europe Long-acting rhG-CSF Sales Breakdown by Application (2021-2026)
  12. 5.3.3 Asia-Pacific Long-acting rhG-CSF Sales Breakdown by Application (2021-2026)
  13. 5.3.4 South America Long-acting rhG-CSF Sales Breakdown by Application (2021-2026)
  14. 5.3.5 Middle East and Africa Long-acting rhG-CSF Sales Breakdown by Application (2021-2026)
6 Company Profiles
  1. 6.1 Yifan Pharmaceutical
  2. 6.1.1 Yifan Pharmaceutical Company Information
  3. 6.1.2 Yifan Pharmaceutical Business Overview
  4. 6.1.3 Yifan Pharmaceutical Long-acting rhG-CSF Sales, Revenue and Gross Margin (2021-2026)
  5. 6.1.4 Yifan Pharmaceutical Long-acting rhG-CSF Product Portfolio
  6. 6.1.5 Yifan Pharmaceutical Recent Developments
  7. 6.2 CSPC
  8. 6.2.1 CSPC Company Information
  9. 6.2.2 CSPC Business Overview
  10. 6.2.3 CSPC Long-acting rhG-CSF Sales, Revenue and Gross Margin (2021-2026)
  11. 6.2.4 CSPC Long-acting rhG-CSF Product Portfolio
  12. 6.2.5 CSPC Recent Developments
  13. 6.3 Sandoz (Novartis)
  14. 6.3.1 Sandoz (Novartis) Company Information
  15. 6.3.2 Sandoz (Novartis) Business Overview
  16. 6.3.3 Sandoz (Novartis) Long-acting rhG-CSF Sales, Revenue and Gross Margin (2021-2026)
  17. 6.3.4 Sandoz (Novartis) Long-acting rhG-CSF Product Portfolio
  18. 6.3.5 Sandoz (Novartis) Recent Developments
  19. 6.4 Qilu Pharmaceutical
  20. 6.4.1 Qilu Pharmaceutical Company Information
  21. 6.4.2 Qilu Pharmaceutical Business Overview
  22. 6.4.3 Qilu Pharmaceutical Long-acting rhG-CSF Sales, Revenue and Gross Margin (2021-2026)
  23. 6.4.4 Qilu Pharmaceutical Long-acting rhG-CSF Product Portfolio
  24. 6.4.5 Qilu Pharmaceutical Recent Developments
  25. 6.5 Mylan
  26. 6.5.1 Mylan Company Information
  27. 6.5.2 Mylan Business Overview
  28. 6.5.3 Mylan Long-acting rhG-CSF Sales, Revenue and Gross Margin (2021-2026)
  29. 6.5.4 Mylan Long-acting rhG-CSF Product Portfolio
  30. 6.5.5 Mylan Recent Developments
  31. 6.6 Pfizer
  32. 6.6.1 Pfizer Company Information
  33. 6.6.2 Pfizer Business Overview
  34. 6.6.3 Pfizer Long-acting rhG-CSF Sales, Revenue and Gross Margin (2021-2026)
  35. 6.6.4 Pfizer Long-acting rhG-CSF Product Portfolio
  36. 6.6.5 Pfizer Recent Developments
  37. 6.7 Jiangsu Hengrui Medicine
  38. 6.7.1 Jiangsu Hengrui Medicine Company Information
  39. 6.7.2 Jiangsu Hengrui Medicine Business Overview
  40. 6.7.3 Jiangsu Hengrui Medicine Long-acting rhG-CSF Sales, Revenue and Gross Margin (2021-2026)
  41. 6.7.4 Jiangsu Hengrui Medicine Long-acting rhG-CSF Product Portfolio
  42. 6.7.5 Jiangsu Hengrui Medicine Recent Developments
  43. 6.8 Fresenius Kabi
  44. 6.8.1 Fresenius Kabi Company Information
  45. 6.8.2 Fresenius Kabi Business Overview
  46. 6.8.3 Fresenius Kabi Long-acting rhG-CSF Sales, Revenue and Gross Margin (2021-2026)
  47. 6.8.4 Fresenius Kabi Long-acting rhG-CSF Product Portfolio
  48. 6.8.5 Fresenius Kabi Recent Developments
  49. 6.9 Amgen Inc.
  50. 6.9.1 Amgen Inc. Company Information
  51. 6.9.2 Amgen Inc. Business Overview
  52. 6.9.3 Amgen Inc. Long-acting rhG-CSF Sales, Revenue and Gross Margin (2021-2026)
  53. 6.9.4 Amgen Inc. Long-acting rhG-CSF Product Portfolio
  54. 6.9.5 Amgen Inc. Recent Developments
  55. 6.10 Spectrum Pharmaceuticals
  56. 6.10.1 Spectrum Pharmaceuticals Company Information
  57. 6.10.2 Spectrum Pharmaceuticals Business Overview
  58. 6.10.3 Spectrum Pharmaceuticals Long-acting rhG-CSF Sales, Revenue and Gross Margin (2021-2026)
  59. 6.10.4 Spectrum Pharmaceuticals Long-acting rhG-CSF Product Portfolio
  60. 6.10.5 Spectrum Pharmaceuticals Recent Developments
  61. 6.11 Coherus BioSciences, Inc.
  62. 6.11.1 Coherus BioSciences, Inc. Company Information
  63. 6.11.2 Coherus BioSciences, Inc. Business Overview
  64. 6.11.3 Coherus BioSciences, Inc. Long-acting rhG-CSF Sales, Revenue and Gross Margin (2021-2026)
  65. 6.11.4 Coherus BioSciences, Inc. Long-acting rhG-CSF Product Portfolio
  66. 6.11.5 Coherus BioSciences, Inc. Recent Developments
  67. 6.12 Biocon Biologics Inc.
  68. 6.12.1 Biocon Biologics Inc. Company Information
  69. 6.12.2 Biocon Biologics Inc. Business Overview
  70. 6.12.3 Biocon Biologics Inc. Long-acting rhG-CSF Sales, Revenue and Gross Margin (2021-2026)
  71. 6.12.4 Biocon Biologics Inc. Long-acting rhG-CSF Product Portfolio
  72. 6.12.5 Biocon Biologics Inc. Recent Developments
7 North America by Country
  1. 7.1 North America Long-acting rhG-CSF Sales by Country
  2. 7.1.1 North America Long-acting rhG-CSF Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 7.1.2 North America Long-acting rhG-CSF Sales by Country (2021-2026)
  4. 7.1.3 North America Long-acting rhG-CSF Sales Forecast by Country (2027-2032)
  5. 7.2 North America Long-acting rhG-CSF Market Size by Country
  6. 7.2.1 North America Long-acting rhG-CSF Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 7.2.2 North America Long-acting rhG-CSF Market Size by Country (2021-2026)
  8. 7.2.3 North America Long-acting rhG-CSF Market Size Forecast by Country (2027-2032)
8 Europe by Country
  1. 8.1 Europe Long-acting rhG-CSF Sales by Country
  2. 8.1.1 Europe Long-acting rhG-CSF Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 8.1.2 Europe Long-acting rhG-CSF Sales by Country (2021-2026)
  4. 8.1.3 Europe Long-acting rhG-CSF Sales Forecast by Country (2027-2032)
  5. 8.2 Europe Long-acting rhG-CSF Market Size by Country
  6. 8.2.1 Europe Long-acting rhG-CSF Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 8.2.2 Europe Long-acting rhG-CSF Market Size by Country (2021-2026)
  8. 8.2.3 Europe Long-acting rhG-CSF Market Size Forecast by Country (2027-2032)
9 Asia-Pacific by Country
  1. 9.1 Asia-Pacific Long-acting rhG-CSF Sales by Country
  2. 9.1.1 Asia-Pacific Long-acting rhG-CSF Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 9.1.2 Asia-Pacific Long-acting rhG-CSF Sales by Country (2021-2026)
  4. 9.1.3 Asia-Pacific Long-acting rhG-CSF Sales Forecast by Country (2027-2032)
  5. 9.2 Asia-Pacific Long-acting rhG-CSF Market Size by Country
  6. 9.2.1 Asia-Pacific Long-acting rhG-CSF Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 9.2.2 Asia-Pacific Long-acting rhG-CSF Market Size by Country (2021-2026)
  8. 9.2.3 Asia-Pacific Long-acting rhG-CSF Market Size Forecast by Country (2027-2032)
10 South America by Country
  1. 10.1 South America Long-acting rhG-CSF Sales by Country
  2. 10.1.1 South America Long-acting rhG-CSF Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 10.1.2 South America Long-acting rhG-CSF Sales by Country (2021-2026)
  4. 10.1.3 South America Long-acting rhG-CSF Sales Forecast by Country (2027-2032)
  5. 10.2 South America Long-acting rhG-CSF Market Size by Country
  6. 10.2.1 South America Long-acting rhG-CSF Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 10.2.2 South America Long-acting rhG-CSF Market Size by Country (2021-2026)
  8. 10.2.3 South America Long-acting rhG-CSF Market Size Forecast by Country (2027-2032)
11 Middle East and Africa by Country
  1. 11.1 Middle East and Africa Long-acting rhG-CSF Sales by Country
  2. 11.1.1 Middle East and Africa Long-acting rhG-CSF Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 11.1.2 Middle East and Africa Long-acting rhG-CSF Sales by Country (2021-2026)
  4. 11.1.3 Middle East and Africa Long-acting rhG-CSF Sales Forecast by Country (2027-2032)
  5. 11.2 Middle East and Africa Long-acting rhG-CSF Market Size by Country
  6. 11.2.1 Middle East and Africa Long-acting rhG-CSF Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 11.2.2 Middle East and Africa Long-acting rhG-CSF Market Size by Country (2021-2026)
  8. 11.2.3 Middle East and Africa Long-acting rhG-CSF Market Size Forecast by Country (2027-2032)
12 Value Chain and Sales Channels Analysis
  1. 12.1 Long-acting rhG-CSF Value Chain Analysis
  2. 12.1.1 Long-acting rhG-CSF Key Raw Materials
  3. 12.1.2 Key Raw Materials Price
  4. 12.1.3 Raw Materials Key Suppliers
  5. 12.1.4 Manufacturing Cost Structure
  6. 12.1.5 Long-acting rhG-CSF Production Mode & Process
  7. 12.2 Long-acting rhG-CSF Sales Channels Analysis
  8. 12.2.1 Direct Comparison with Distribution Share
  9. 12.2.2 Long-acting rhG-CSF Distributors
  10. 12.2.3 Long-acting rhG-CSF Customers
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources
    8. 14.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst